- Home
- MOBX vs ALLR Comparison
MOBX vs ALLR Comparison
Compare MOBX & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MOBX | ALLR |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0M | 19.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MOBX | ALLR |
|---|---|---|
| Price | $0.19 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | ★ 26.1M | 180.1K |
| Earning Date | 02-12-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,912,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.87 | N/A |
| 52 Week Low | $0.17 | $0.61 |
| 52 Week High | $1.44 | $2.35 |
Technical Indicators
Market Signals| Indicator | MOBX | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 36.37 | 33.22 |
| Support Level | $0.20 | $0.83 |
| Resistance Level | $0.34 | $1.00 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 5.33 | 13.91 |
Price Performance
Historical ComparisonAbout MOBX Mobix Labs Inc.
Mobix Labs Inc. specializes in designing, developing, and selling components and systems for wireless and wired connectivity, radio frequency (RF) technologies, switching, and electromagnetic interference (EMI) filtering solutions. The company serves markets, including commercial, industrial, automotive, medical, aerospace, defense, and others.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.